Dewit L, Ang K K, Van der Schueren E
Cancer Treat Rev. 1983 Jun;10(2):79-89. doi: 10.1016/0305-7372(83)90006-3.
In the last two decades, many authors have treated prostatic carcinoma by radiation therapy. Accumulated data have been updated, after 10 and 15 years of follow-up. In stage A and B, the reported survival and local control rates after irradiation (20, 22, 30, 34, 35, 39, 42) are as good as in selected patients treated by radical prostatectomy (9, 18, 23). In stage C, the results after irradiation (20, 22, 30, 42) are better than after radical surgery (23, 43). However, patients are nonrandomly selected and the methods of statistical analysis differ. Therefore, a valid comparison cannot be made. The therapeutic ratio is determined by survival and local control, and also by therapy related complications. It is therefore of interest to find out from radiotherapy series if their incidence is related to the treatment technique. Unfortunately, relatively few studies accurately describe treatment technique and complications. Gastro-intestinal radiation injury becomes significant when the dose at the posterior rectal wall is 65-76 Gy and the length of the treated rectum is at least 10 cm. A hot spot of 80-84 Gy needs to be only 2 to 3 cm to increase the risk of late bowel stenosis. Genito-urinary complications are influenced by local extension of the tumor and by previous surgical manipulations. A dose at the prostatic area exceeding 70 Gy should be avoided, as it does not improve local control (22, 35) and apparently increases the risk of late urethral stricture and penile/scrotal edema (12, 39). The dose at the anterior bladder wall correlates with other types of genito-urinary complications. Therefore, the anterior bladder wall should not receive a dose higher than 65 Gy. Incidence of impaired potency after irradiation is usually 30 to 40%, which is much less than after radical surgery. As many data in the literature dealing with radiation treatment of the prostate are still inadequate a more standardized reporting is recommended to make comparison of effectiveness and side effects possible.
在过去二十年中,许多作者采用放射治疗前列腺癌。经过10年和15年的随访,积累的数据已得到更新。在A期和B期,报道的放疗后生存率和局部控制率(20、22、30、34、35、39、42)与接受根治性前列腺切除术的特定患者相当(9、18、23)。在C期,放疗后的结果(20、22、30、42)优于根治性手术后的结果(23、43)。然而,患者是经过非随机选择的,统计分析方法也不同。因此,无法进行有效的比较。治疗比由生存率、局部控制率以及治疗相关并发症决定。因此,从放疗系列研究中了解并发症的发生率是否与治疗技术相关很有意义。不幸的是,相对较少的研究准确描述了治疗技术和并发症。当直肠后壁剂量为65 - 76 Gy且治疗的直肠长度至少为10 cm时,胃肠道放射性损伤会变得显著。80 - 84 Gy的热点仅需2至3 cm就会增加晚期肠道狭窄的风险。生殖泌尿系统并发症受肿瘤局部扩展和既往手术操作的影响。应避免前列腺区域剂量超过70 Gy,因为这并不能改善局部控制(22、35),而且明显增加了晚期尿道狭窄和阴茎/阴囊水肿的风险(12、39)。膀胱前壁剂量与其他类型的生殖泌尿系统并发症相关。因此,膀胱前壁不应接受高于65 Gy的剂量。放疗后性功能障碍的发生率通常为30%至40%,远低于根治性手术后的发生率。由于文献中许多关于前列腺放射治疗的数据仍然不足,建议采用更标准化的报告方式,以便能够比较疗效和副作用。